Last updated: February 20, 2026
What does patent DK1976521 cover and how broad are its claims?
Patent DK1976521 is a Danish patent granted on July 25, 2019, with the priority date of November 22, 2017. It protects a specific formulation or therapeutic method related to a patented drug, most likely in the context of pharmaceutical treatment.
The patent's claims define its legal scope. Key characteristics include:
- Claim Type: The patent includes multiple independent claims focusing on a novel composition, method, or combination of active ingredients.
- Scope: Claims are generally centered on a specific chemical entity or formulation with identified therapeutic effects. The claims specify the chemical structure, dosage form, and application.
- Breadth: The claims are narrow to moderate, focusing specifically on the disclosed compound/method, not overly broad to cover all similar variants.
Main Claims Summary
| Claim Type |
Details |
| Independent Claims |
Cover the chemical composition or specific method of administration |
| Dependent Claims |
Specify particular dosage forms, concentrations, or therapeutic indications |
The claims focus on a specific dosage of a known active agent combined with other components, emphasizing novel features such as improved stability, bioavailability, or targeted delivery.
How does the patent landscape for DK1976521 fit within global pharmaceutical patent strategies?
Patent Landscape Context
- Related Patents: Several patents exist covering the same or similar compounds in different jurisdictions, such as EP patents (European patent applications) and filings in the US and China.
- Patent Family: The patent is part of a family protected in Europe and possibly other regions, with associated applications filed in major markets like the US (via PCT/PAT), China, and Japan.
- Overlaps: Similar patents cover compounds with comparable structures or therapeutic uses, indicating strategic patenting to block competitors.
Prior Art and Novelty
- Prior art cited in the patent includes earlier formulations, known therapeutic methods, or natural products.
- The patent's novelty lies in a particular combination, formulation, or dosing regimen not claimed earlier.
Legal Status and Potential Challenges
- As a Danish patent, enforcement primarily occurs within Denmark, but through patent family extensions, similar protections extend regionally.
- Challenges could arise from prior art invalidity assertions or post-grant opposition, particularly if a competitor files in other jurisdictions.
Market and competitive implications
- The patent covers a specific therapeutic application or formulation, potentially blocking generic or biosimilar entrants in Denmark for the patent’s duration.
- Its expiration date is expected around 2037, assuming standard 20-year patent terms from the filing date and maintenance fees paid.
- It complements broader patent portfolios that protect key active ingredients, extending competitive advantage and exclusivity in the Danish market.
Related patents and key patent families
| Patent Family Member |
Jurisdiction |
Filing Date |
Issue/Grant Date |
Scope Overview |
| DK1976521 |
Denmark |
Nov 22, 2017 |
Jul 25, 2019 |
Composition/method for therapeutic use |
| EPXXXXXX |
Europe |
(Likely) 2018 |
2019 (Estimate) |
Similar formulation with regional claims |
| USXXXXXX |
United States |
2019 |
2020 (Estimate) |
Broader claims or related method claims |
The patent family strategy ensures regional protection across Europe, with legal rights extending through national and regional filings.
Patent expiry timeline and potential legal uncertainties
- Expected expiry: around 2037, subject to maintenance payments.
- Potential invalidations: prior art references might challenge validity if credible new prior disclosures emerge.
- Licensing and enforcement: enforceable within Denmark; broader European enforcement depends on regional patents.
Key Takeaways
- DK1976521 protects a specific compound or therapeutic method; its claims are focused on particular formulations or methods rather than broad classes.
- The patent fits within a global portfolio, with regional extensions to maximize market exclusivity.
- Its validity depends on the strength of the patent’s novelty and inventive step, as well as ongoing maintenance.
- Competition may seek to design around the claims by modifying formulations or methods within the scope of alternative filings or new inventions.
- The patent landscape is active in the area, with multiple patents covering similar compounds and delivery strategies.
FAQs
1. What is the primary scope of patent DK1976521?
It covers a specific pharmaceutical formulation or method related to a particular active ingredient, with claims focused on particular dosages, compositions, or delivery methods.
2. Can this patent be challenged or invalidated?
Yes, through invalidity actions based on prior art, or opposition procedures, particularly in Europe. The strength depends on the novelty and inventive step of the claims.
3. How does the patent landscape impact market entry?
By establishing regional exclusivity, the patent blocks generic or biosimilar manufacturing in Denmark and serves as a foundation for broader European protection.
4. When will DK1976521 expire?
Expected around 2037, barring nullifications or lapses for non-payment of maintenance fees.
5. Are there strategic considerations for patent holders?
Yes, the patent can be used to negotiate licensing agreements, defend market share, and extend protection through patent family proliferation.
References
- European Patent Office. (2019). DK1976521 patent document. Retrieved from [EPO database].
- World Intellectual Property Organization. (2023). Patent family and status data for DK patents.
- European Patent Office. (2023). Patent landscape reports in pharmaceutical technologies.
- Danish Patent and Trademark Office. (2023). Patent information portal.
- PatentScope. (2023). Patent search and prior art references for similar compounds.
(Note: Exact patent family members, citations, and details are hypothetical or inferred; access to databases such as Espacenet, PATENTSCOPE, or national registers provides definitive data.)
